Journal of the American Society of Hypertension
Volume 4, Issue 5 , Pages 219-226 , September 2010

Effects of the renin inhibitor MK-8141 (ACT-077825) in patients with hypertension

  • Charlotte Jones-Burton, MD, MS

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • Corresponding Author InformationCorresponding Author: Charlotte Jones-Burton, MD, MS, Merck Sharp and Dohme Corp., RY 34-A258, 126 East Lincoln Avenue, Rahway, NJ 07065. Tel: 732-594-7686; fax: 215-661-6757.
    • ,
  • Joseph Rubino, MBA

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Sophie Roy, PhD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Yabing Mai, PhD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Alan Meehan, PhD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA
    • ,
  • Marc Bellet, MD

      Affiliations

    • Actelion Pharmaceuticals Ltd., Allschwil, Switzerland
    • ,
  • Peter Feig, MD

      Affiliations

    • Merck Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, New Jersey, USA

Received 24 May 2010 ,Accepted 24 June 2010.

References 

  1. Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995;155:405–411
  2. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449–1456
  3. Kruma H, Gilbert RE. Novel therapies blocking the renin–angiotensin–aldosterone system in the management of hypertension and related disorders. J Hypertens. 2007;25:25–35
  4. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Weber B, et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564–572
  5. Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlöf B, Deanfield J, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Card Drugs Ther. 2002;16:149–160
  6. Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005;115:1092–1099
  7. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension. 2002;39:e1–e8
  8. Azizi M, Bissery A, Lamarre-Cliché M, Menard J. Integrating drug pharmacokinetics for phenotyping individual renin response to angiotensin II blockade in humans. Hypertension. 2004;43:785–790
  9. Gradman AH, Schmeider RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–1018
  10. Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–226
  11. Pool JL, Schmieder RE, Azizi M, Aldigier J-C, Januszewicz A, Zidek W, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11–20
  12. Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157–1163
  13. Stanton A, Jensen C, Nussberger J, O’Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137–1143
  14. O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension. 2007;49:276–284
  15. Nussberger J, Gradham AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract. 2007;61:1461–1468
  16. U.S. product circular for Tekturna (aliskiren). Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021985lbl.pdf. Accessed July 9, 2010.
  17. Fischli W, Clozel JP, Breu V, Buchmann S, Mathews S, Stadler H, et al. Ciprokiren (Ro-44-9375)—a renin inhibitor with increasing effects on chronic treatment. Hypertension. 1994;24:163–169
  18. Clozel JP, Fischli W, Menard J. Effects of the blockade of the renin-angiotensin system in cyclosporine-induced hypertension. J Hypertens. 1993;11:75–81
  19. Behm MO, Dingemanse J, Nicolas LB, Harris D, Taylor A, Treiber A, et al. A drug-drug interaction study of MK-8141/ACT-077825 co-administered with midazolam to evaluate concurrent CYP3A4 induction and inhibition potential. J Clin Pharmacol. 2009;49:1113
  20. Nicolas L, Binkert C, Jungnik A, Dingemanse J. Integrated clinical pharmacology of a new renin inhibitor during the first study in humans. Clin Pharmacol Ther. 2009;85(Suppl 1):S70
  21. Nicolas LB, Binkert C, Jungnik A, Behm MO, Harris DE, Murphy G, et al. Clinical pharmacology of multiple ascending doses of ACT-077825/MK-8141, a new renin inhibitor. J Clin Pharmacol. 2009;49:1110
  22. Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre-post designs. Sankhya Ind J Stat. 2000;62(Series B):134–148
  23. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens. 2009;22:112–121

 This study was jointly funded by Merck & Co. Inc. and Actelion Pharmaceuticals Ltd. C. Jones-Burton, J. Rubino, S. Roy, Y. Mai, A. Meehan, and P. Feig are employees of Merck, Sharp and Dohme Corp., a subsidiary of Merck & Co., Inc., and may hold stock/stock options in the company. M. Bellet is an employee of Actelion Pharmaceuticals Ltd.

PII: S1933-1711(10)00125-7

doi: 10.1016/j.jash.2010.06.006

Journal of the American Society of Hypertension
Volume 4, Issue 5 , Pages 219-226 , September 2010

Article Tools

* Image Usage & Resolution